226 related articles for article (PubMed ID: 38343381)
1. Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.
Espinosa De Ycaza AE; Brito JP; McCoy RG; Shao H; Singh Ospina N
Thyroid; 2024 Apr; 34(4):403-418. PubMed ID: 38343381
[No Abstract] [Full Text] [Related]
2. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
Drab SR
Curr Diabetes Rev; 2016; 12(4):403-413. PubMed ID: 26694823
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.
Silverii GA; Monami M; Gallo M; Ragni A; Prattichizzo F; Renzelli V; Ceriello A; Mannucci E
Diabetes Obes Metab; 2024 Mar; 26(3):891-900. PubMed ID: 38018310
[TBL] [Abstract][Full Text] [Related]
5. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
6. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
7. Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis.
Makunts T; Joulfayan H; Abagyan R
JMIRx Med; 2024 May; 5():e55976. PubMed ID: 38738836
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.
Górriz JL; Romera I; Cobo A; O'Brien PD; Merino-Torres JF
Diabetes Ther; 2022 Mar; 13(3):389-421. PubMed ID: 35175551
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.
Jensterle M; Janež A
Horm Res Paediatr; 2023; 96(6):599-608. PubMed ID: 34852347
[TBL] [Abstract][Full Text] [Related]
11. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
He L; Wang J; Ping F; Yang N; Huang J; Li Y; Xu L; Li W; Zhang H
JAMA Intern Med; 2022 May; 182(5):513-519. PubMed ID: 35344001
[TBL] [Abstract][Full Text] [Related]
12. Perioperative management of patients on glucagon-like peptide-1 receptor agonists.
Mizubuti GB; Ho AM; Silva LMD; Phelan R
Curr Opin Anaesthesiol; 2024 Jun; 37(3):323-333. PubMed ID: 38390914
[TBL] [Abstract][Full Text] [Related]
13. Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.
Akbari A; Hadizadeh S; Heidary L
J Diabetes Res; 2024; 2024():3212795. PubMed ID: 38529046
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database.
Mali G; Ahuja V; Dubey K
J Clin Pharm Ther; 2021 Feb; 46(1):99-105. PubMed ID: 32926446
[TBL] [Abstract][Full Text] [Related]
16. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
17. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure.
Ferreira JP; Sharma A; Butler J; Packer M; Zannad F; Vasques-Nóvoa F; Leite-Moreira A; Neves JS
J Clin Endocrinol Metab; 2023 Dec; 109(1):4-9. PubMed ID: 37409733
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
20. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]